Research Reports

Key takeaways

Private placement of 5,208,333 ADSs at $0.48 per ADS with Series A warrants ($0.48 exercise price, 2-year term) and Series B warrants ($0.55 exercise price, 5-year term).

Warrant inducement: exercise of existing warrants for 229,310 ADSs at $0.48 per ADS, receiving new warrants for 458,621 ADSs at $0.55 exercise price, 5-year term.

Aggregate gross proceeds of approximately $2.61 million before fees.

Proceeds to support CDMO platform expansion, customer programs, and immunotherapy pipeline.

Securities issued under Section 4(a)(2) exemption, not registered.

Closing expected on or about April 27, 2026, subject to customary conditions.

Full analysis

Scinai Immunotherapeutics executed a strategic private placement raising $2.61 million gross proceeds via 5,208,333 ADSs priced at $0.48 each, accompanied by Series A warrants (exercisable at $0.48, 2-year term) and Series B warrants (exercisable at $0.55, 5-year term), each covering 5,208,333 ADSs. Concurrently, an existing institutional investor exercised warrants for 229,310 ADSs at a reduced $0.48 per ADS, receiving inducement New Warrants for 458,621 ADSs at $0.55 exercisable over 5 years. The transaction, led by A.G.P./Alliance Global Partners, leverages Section 4(a)(2) exemption with registration rights via Exhibit 10.2. Pre-funded warrants in Exhibit 4.1 feature nominal $0.0001 exercise price with full funding prepaid. Closing targeted for April 27, 2026 supports CDMO growth at Scinai Biopharma Services and pipeline advancement, signaling investor confidence in the immunology and manufacturing platforms amid capital needs.

SCNI · Scinai Immunotherapeutics Ltd.

Summary

Key takeaways

Full analysis